Huayu Pharmaceuticals expects the annual net profit attributable to shareholders to be a loss of 24-29 million yuan in 2025.

Huiyu Pharmaceutical announced that it is expected to incur a net loss attributable to shareholders of 29 million yuan to 24 million yuan in the fiscal year 2025, a year-on-year decrease of 108.91% to 107.38% compared to the same period last year. The company's invested enterprise, Zhejiang Tongyuan Kang Medicine Co., Ltd., was listed on the Hong Kong Stock Exchange market on August 20, 2024, in accordance with the HKEx 18A listing standards. The fair value change loss during the reporting period was 173 million yuan due to fluctuations in the stock price of the invested enterprise.